Patients with orofacial pain lasting at least for 3 months .The patients will be randomly
assigned to one of the two groups according to the treatment method: group I (intraoral
injection) and group II (transcutaneous injection) where each patient injected BTA in each
TrPs according to the treatment group by the same operator. Patients will be examined by a
blinded investigator at pre- and post-injections at the following intervals: during
diagnosis, 1-week, 4-weeks, and 6-weeks post-injection. The patients will be assessed using
pain score measured on a 10-point visual analogue scale (VAS). The secondary outcome assessed
will be measuring the quality-of-life in an Oral Health Impact Profile questionnaire
(OHIP-14).